Amylin analogue mechanism: satiety signalling separate from GLP-1 posts 121–143

On amylin analogue mechanism I would separate what is worth knowing from what is worth acting on. The first list is long and the second is short, and conflating them is how threads get heated.

Reporting rather than recommending, on amylin analogue mechanism. What happened is above. Whether it should have is a different question and not one I am qualified to answer.

The arithmetic in post #120 is right; the assumption feeding it is the part to check.

The phase 3 combination programme is where the clinically interesting numbers will come from. Phase 2 established that the combination does something; the size of it in a larger population is a separate question.

Filing this under things that are true until someone shows me otherwise.

Answering the question post #122 raises rather than the one it answers.

Native amylin has awkward physical properties — it aggregates readily, which is why a stable analogue is a pharmaceutical achievement rather than a formulation detail.

It took me longer than it should have to see that.

Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and analytically straightforward to confirm by LC-MS.

Flagging that the sources on this are thinner than the confidence in the thread suggests.

On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.

Appreciated. The plain phrasing does more work here than a longer post would.

Post #126 describes the usual case. This is about the unusual one.

Anyone submitting this for independent testing should say in the submission that it is an amylin analogue rather than an incretin. Method selection differs and a default incretin gradient is not necessarily the right one.

If this contradicts something upthread, the upthread version may well be the better one.

Taking post #128 at face value and following it one step further.

Is synergy the right word for the combination data? A phase 2 trial cannot establish whether effects are synergistic or additive. Synergy is a mechanistic claim that requires a designed experiment to support it. The combination works, but the mechanism is unsettled.

The rule of thumb is fine; the edge cases are where it earns its keep.

Post #126 and I disagree about the size of the effect, not about the direction.

What is genuinely unknown about long-term amylin agonism: real-world response rates, whether effect is durable with continued use, whether satiety adaptation occurs over months or years, safety profile in populations not enrolled in the trials.

The evidence for this is thinner than the way I have phrased it suggests.

No disagreement from me. Posting only so the question does not look ignored.

Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably together and both are true.

The honest summary of the evidence base: a coherent mechanism, good phase 2 data in combination, and much less standalone human data than the volume of discussion implies.

Adding the measurement that post #133 says would settle it.

Small correction to my own earlier position on amylin analogue mechanism. I had the units the wrong way round, which changes the conclusion by an order of magnitude and therefore changes it entirely.